Markets:

Overview

News

Currencies

International

Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

8.680 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data ↗

August 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS...

Via Benzinga

Where Sage Therapeutics Stands With Analysts ↗

August 04, 2021

Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE...

Via Benzinga

Overview Of Value Stocks In The Healthcare Sector ↗

August 16, 2021

Understanding Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be...

Via Benzinga

A Look Into Healthcare Sector Value Stocks ↗

August 09, 2021

What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be...

Via Benzinga

Sage Therapeutics to Present at Upcoming August Investor Conferences

August 04, 2021

From Sage Therapeutics, Inc.

Via Business Wire

10 Biggest Price Target Changes For Wednesday ↗

August 04, 2021

Baird boosted the price target for Lululemon Athletica Inc. (NASDAQ:

Via Benzinga

Sage Therapeutics Inc (SAGE) Q2 2021 Earnings Call Transcript ↗

August 03, 2021

SAGE earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Analyst Ratings For Sage Therapeutics ↗

July 29, 2021

Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:

Via Benzinga

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗

July 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...

Via Benzinga

The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings ↗

August 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

Sage Therapeutics Drops Two Zuranolone Depression Trials Deemed Unnecessary For Approval ↗

August 03, 2021

Tucked in the Q2 earnings release, Sage Therapeutics Inc (NASDAQ: SAGE) has terminated two long-suspended Phase 3 zuranolone trials in major depressive disorder (MDD)....

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

August 03, 2021

On Tuesday morning, 69 companies achieved new lows for the year. Intriguing Points: Las Vegas Sands (NYSE:LVS) was the largest firm by market cap to set a new 52-...

Via Benzinga

Sage Therapeutics: Q2 Earnings Insights ↗

August 03, 2021

Shares of Sage Therapeutics (NASDAQ:SAGE) moved higher by 11.9% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 12...

Via Benzinga

Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

August 03, 2021

From Sage Therapeutics, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Tuesday ↗

July 27, 2021

During Tuesday's morning session, 216 companies made new 52-week lows. Noteworthy Points: Alibaba Group Holding (NYSE:BABA) was the largest firm by market cap...

Via Benzinga

Earnings Scheduled For August 3, 2021 ↗

August 03, 2021

Companies Reporting Before The Bell • Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter. • Stellantis (NYSE:STLA) is expected to...

Via Benzinga

The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts ↗

July 27, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI...

Via Benzinga

Sage Therapeutics to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021

July 20, 2021

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics to Participate in Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Summit

July 08, 2021

From Sage Therapeutics, Inc.

Via Business Wire

June’s Best and Worst Performing Russell 1,000 Stocks ↗

June 29, 2021

The month of June, the second quarter and the first half of 2021 are almost in the bag.

Via Talk Markets

How Bad Is Biogen's Latest Bad News? ↗

June 29, 2021

The drugmaker has had one big clinical setback and another less serious disappointment in recent weeks.

Via The Motley Fool

Sage Therapeutics to Participate in SVB Leerink’s 3rd Annual CNS Forum

June 24, 2021

From Sage Therapeutics, Inc.

Via Business Wire

What Happened to Sage Therapeutics Stock? ↗

June 21, 2021

Sage has been struggling for some time to bring its flagship antidepressant to the market.

Via The Motley Fool

Looking For Bargains Among The Rubble ↗

June 20, 2021

Last week was tough. Nearly everything publicly traded took a hit. In this article I drill down into the market to take account of where the damage was the worst, and maybe identify a few bargains...

Via Talk Markets

Here's Why Sage Therapeutics Tanked This Week ↗

June 19, 2021

The neuroscience-focused biotech company didn't give investors the result they wanted.

Via The Motley Fool

Biogen Discontinues Tau Antibody Program For Alzheimer's After Mid-Stage Study Flops ↗

June 17, 2021

Biogen Inc (NASDAQ: BIIB) has four other Alzheimer’s candidates in its clinical pipeline behind recently-approved Aduhelm, of which one has just been canned. The...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2021 ↗

June 16, 2021

Upgrades According to Piper Sandler, the prior rating for First Bancorp (NASDAQ:

Via Benzinga

10 Biggest Price Target Changes For Wednesday ↗

June 16, 2021

Morgan Stanley raised NIKE, Inc. (NYSE:NKE) price ta...

Via Benzinga

44 Biggest Movers From Yesterday ↗

June 16, 2021

Gainers Alzamend Neuro, Inc. (NASDAQ: ALZN) shares jumped 170% to close at $13.50 on Tuesday after the company priced its IPO at $5 per share. Alfi, Inc. (NASDAQ: ALF) shares...

Via Benzinga

Topics Initial Public Offering

Mid-Afternoon Market Update: Nasdaq Down 100 Points; Clearside Biomedical Shares Spike Higher ↗

June 15, 2021

Toward the end of trading Tuesday, the Dow traded down 0.19% to 34,326.95 while the NASDAQ fell 0.70% to 14,074. The S&P also fell, dropping 0.12% to 4,249.99. The U.S. has...

Via Benzinga

Topics Stocks

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.